[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370226-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370226-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","molecular-characterization-of-her2-negative-breast-cancers-reveals-a-distinct-patient-subgroup-with-17q12-deletion-and-heterozygous-loss-of-erbb2","Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2","","Study focuses on HER2-negative (HER2−) breast cancers, where clinical subgrouping based on immunohistochemistry has uncertain biological meaning. Using transcriptomic and genomic data from a discovery cohort and an independent validation cohort, HER2− tumors were stratified by quantitative ERBB2 mRNA into minimal, moderate, and enhanced groups. Enhanced tumors showed higher PIK3CA mutation prevalence and estrogen receptor signaling, whereas minimal tumors showed more proliferation and immune-related gene expression. A distinct subgroup with 17q12 deletion and heterozygous ERBB2 loss displayed very low ERBB2 mRNA and HER2 protein and worse overall survival in real-world cohorts.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-characterization-of-her2-negative-breast-cancers-reveals-a-distinct-patient-subgroup-with-17q12-deletion-and-heterozygous-loss-of-erbb2/370226/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-characterization-of-her2-negative-breast-cancers-reveals-a-distinct-patient-subgroup-with-17q12-deletion-and-heterozygous-loss-of-erbb2/370226.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"How were HER2-negative breast cancers subgrouped in this study?","Question",{"text":63,"@type":64},"HER2-negative tumors were stratified using quantitative ERBB2 (HER2) mRNA levels, dividing cases into minimal, moderate, and enhanced subgroups.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What molecular differences were observed between the ERBB2 mRNA subgroups?",{"text":68,"@type":64},"Enhanced ERBB2 mRNA tumors showed more PIK3CA mutations and increased estrogen receptor signaling, while minimal ERBB2 mRNA tumors showed higher proliferation and immune-related gene expression.",{"name":70,"@type":61,"acceptedAnswer":71},"What defines the distinct patient subgroup identified by the study?",{"text":72,"@type":64},"The distinct subgroup is characterized by a large deletion of chromosome 17q12 (17q12del) with heterozygous loss of ERBB2, alongside very low ERBB2 mRNA and HER2 protein expression.",{"name":74,"@type":61,"acceptedAnswer":75},"How did the 17q12del/heterozygous ERBB2 loss subgroup impact patient outcomes?",{"text":76,"@type":64},"Across two large real-world cohorts of HER2-negative metastatic breast cancer, patients in this subgroup had poorer overall survival.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370226,1790336454,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,104,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":55,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":116,"preview_page_count":33,"preview_urls":149},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ORIGINAL ARTICLE  \nMolecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2  \nX. Qiu1 , 2y, P. Tarantino2, 3, 4y, R. Li1, 2y, A. Grinshpun2 , 3, H. Gupta2, 5, M. E. Hughes2 , 3, G. Kirkner2, 3, L. Scholl2, B. E. Johnson2, M. Meyerson2 , 5, A. D. Cherniack2, 5, Y. Jiang1, 2, N. Zhou1 , 2, N. U. Lin2, 3, H. W. Long1, 2, S. M. Tolaney2, 3 & R. Jeselsohn1, 2, 3 􀀂  \n1Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston; 2Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 3Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Boston, USA; 4Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; 5Broad Institute of Harvard and MIT, Cambridge, USA  \nAvailable online xxx  \nBackground: The approval of trastuzumab deruxtecan has prompted the subgrouping of human epidermal growth factor receptor 2-negative (HER2􀀃) breast cancers (BCs) to HER2 0 and HER2 low on the basis of immunohistochemistry, although the biological signiﬁcance of these subgroups remains uncertain. This study is aimed to better understand the molecular and genetic differences among HER2 􀀃 tumors stratiﬁed by quantitative levels of HER2 .  \nPatients and methods: We analyzed the transcriptomic and genomic data from the Molecular Taxonomy of BC International Consortium (discovery cohort) and The Cancer Genome Atlas (independent validation cohort) . HER2 􀀃 BCs, including hormone receptor positive and triple negative, were divided into three subgroups based on ERBB2 messenger RNA (mRNA) levels: minimal, moderate and enhanced.  \nResults: We observed signiﬁcant differences in mutational and transcriptional proﬁles across the subgroups. Tumors with enhanced ERBB2 mRNA expression had a higher prevalence of PIK3CA mutations and increased estrogen receptor signaling, while tumors with minimal ERBB2 mRNA expression displayed higher expression of proliferation and immune-related genes. We identiﬁed a distinct subgroup of BCs characterized by a large deletion of chromosome 17q12 (17q12del) with heterozygous loss of ERBB2, very low ERBB2 mRNA and HER2 protein expression. This subgroup was also enriched for heterozygous losses of TP53 and other tumor suppressor genes. Analysis of two large real-world cohorts of patients with HER2 􀀃 metastatic BC (Dana-Farber Cancer Institute cohort n ¼ 1063 and Memorial Sloan Kettering MetTropism cohort n ¼ 1018) showed that patients with 17q12del and heterozygous loss of ERBB2 had poorer overall survival (OS) .  \nConclusions: We identiﬁed a biologically and clinically distinct subgroup of BCs characterized by a 17q12del with a heterozygous loss of ERBB2 and low ERBB2 mRNA and HER2 protein expression. In two large real-world cohorts of patients with HER2 􀀃 metastatic BC, this subgroup was associated with poor OS, highlighting its clinical signiﬁcance. Key words: breast cancer, HER2 low, ERBB2 mRNA, ERBB2 heterozygous loss  \nINTRODUCTION  \nHuman epidermal growth factor receptor 2 (HER2)-positive breast cancers (BCs) based on immunohistochemistry (IHC) and FISH testing and the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines are an established biological distinct subgroup of  \n*Correspondence to: Dr Rinath Jeselsohn, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Tel: þ1-617-632-3800  \nE-mail: [rinath_jeselsohn@dfci.harvard.edu](rinath_jeselsohn@dfci.harvard.edu) (R. Jeselsohn).  \nyBoth authors contributed equally.  \n2059-7029/© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nBCs with unique molecular characteristics and sensitivity to HER2-directed treatments. In the ","cbCaim460gKoh0Py","https://ap.wps.com/l/cbCaim460gKoh0Py","pdf",1138927,12,"English","# Background\n# Patients and methods\n## Study cohorts and design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"How were HER2-negative breast cancers subgrouped in this study?\",\"answer\":\"HER2-negative tumors were stratified using quantitative ERBB2 (HER2) mRNA levels, dividing cases into minimal, moderate, and enhanced subgroups.\"},{\"question\":\"What molecular differences were observed between the ERBB2 mRNA subgroups?\",\"answer\":\"Enhanced ERBB2 mRNA tumors showed more PIK3CA mutations and increased estrogen receptor signaling, while minimal ERBB2 mRNA tumors showed higher proliferation and immune-related gene expression.\"},{\"question\":\"What defines the distinct patient subgroup identified by the study?\",\"answer\":\"The distinct subgroup is characterized by a large deletion of chromosome 17q12 (17q12del) with heterozygous loss of ERBB2, alongside very low ERBB2 mRNA and HER2 protein expression.\"},{\"question\":\"How did the 17q12del/heterozygous ERBB2 loss subgroup impact patient outcomes?\",\"answer\":\"Across two large real-world cohorts of HER2-negative metastatic breast cancer, patients in this subgroup had poorer overall survival.\"}]","Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2 | PDF",1790187468,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71a51d2374da6654afe281718566285f.webp",983,1269,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18f3b4f50dfb3ce8777afdfeb507cea8.webp",982,1268,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f32e969bc33658bbefead7aa91886bd.webp",981,1266,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/961c6b404b0e0828ee3d4acbb7d793f2.webp",980,1265]